[Skip to Navigation]
October 2018

Cervical Cancer Screening—Moving From the Value of Evidence to the Evidence of Value

Author Affiliations
  • 1Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco
  • 2Department of Epidemiology & Biostatistics, University of California, San Francisco
  • 3Center for Healthcare Value, University of California, San Francisco
JAMA Intern Med. 2018;178(10):1293-1295. doi:10.1001/jamainternmed.2018.4282

Widespread implementation of cytology-based screening programs has resulted in marked declines in cervical cancer incidence and mortality in the United States. Nonetheless, an estimated 13 240 women will be diagnosed with cervical cancer in 2018, and 4170 will die from the disease.1 It is likely that a sizable proportion of these women will not have been appropriately screened.2

Add or change institution